HUTCHMED Details SAFFRON and SANOVO Phase III Wins at ESMO, SAFFRON Published in NEJM
HCM sits 58% above its 52-week low of $9.77 on light trading volume (0.3× avg).
Summary
HUTCHMED released full SAFFRON and SANOVO Phase III data at ESMO, with SAFFRON also published in the New England Journal of Medicine. The detailed survival numbers back the already-submitted US NDA and a planned China filing for first-line use.
Key Events · Product Development and Regulatory · HCM
-
SAFFRON Survival Benefit Quantified
ORPATHYS plus TAGRISSO reduced the risk of progression or death by 45% (PFS HR 0.55) and the risk of death by 32% (OS HR 0.68) versus chemotherapy, with median OS of 17.8 versus 12.9 months.
-
SANOVO First-Line PFS Nearly Doubled
In treatment-naive MET-overexpressing EGFR-mutated NSCLC, median PFS was 24.9 versus 13.8 months (HR 0.56) and median OS 44.5 versus 34.9 months (HR 0.48) versus TAGRISSO alone.
-
NEJM Publication Adds Validation
The SAFFRON results were simultaneously published in The New England Journal of Medicine 2026 alongside the ESMO Presidential Symposium presentation.
-
Regulatory Filings Advancing
A US NDA for the SAFFRON setting is already submitted, Europe and Japan submissions are progressing, and HUTCHMED plans a supplemental China NDA for the SANOVO first-line setting.
Analysis · HCM · Life Sciences
The August topline releases said the trials worked; this filing shows how well. In SAFFRON, adding ORPATHYS to TAGRISSO cut the risk of progression or death by 45% and the risk of death by 32% versus chemotherapy in MET-driven EGFR-mutated lung cancer after TAGRISSO failure, extending median overall survival by 4.9 months (17.8 vs 12.9). SANOVO, in the first-line setting, roughly doubled median progression-free survival to 24.9 months from 13.8 and extended median overall survival by 9.6 months (44.5 vs 34.9). Those are the kind of numbers that support regulatory filings and, if approved, a durable commercial franchise for the ORPATHYS plus TAGRISSO combination that AstraZeneca commercializes and HUTCHMED shares in. The US NDA for the SAFFRON setting is already submitted, with Europe and Japan progressing, and HUTCHMED plans a supplemental China NDA for the first-line SANOVO setting. Simultaneous publication in the New England Journal of Medicine adds external validation that matters to prescribers and payers.
How filings like this one have moved
In the 30 days to Oct 26, 2026, 36.2% of the 898 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.75%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, HCM was trading at $15.41 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $2.5B. The 52-week trading range was $9.77 to $16.33. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.